| 1 |
What is the primary function of AI in the medical imaging industry?
|
To improve diagnostic accuracy and patient outcomes |
|
AI helps doctor analyze medical images faster and more accurately, which leads to better diagnoses and treatment for patients. |
This is related to AI-assisted diagnosis, where technology supports medical professionals to make more precise decisions, improving healthcare quality.
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
Which of the following is a key benefit of AI in radiology noted in the article?
|
Acts as a second medical opinion |
|
The article said AI can double-check what the radiologist sees. It’s like having a smart assistant that helps spot things the doctor might miss. |
This connects to decision support systems, where AI works alongside doctors to make diagnoses more accurate and reliable.
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
What does AI literacy refer to according to the article?
|
Understanding and knowledge of AI technology |
|
AI literacy means knowing what AI is, how it works, and how to use it properly.Especially in medical settings where it can support doctors and improve care. |
This connects to the idea of healthcare AI readiness, which says professionals should understand AI well enough to trust and use it responsibly. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
Which factor is NOT listed as influencing the acceptability of AI among healthcare professionals?
|
The color of the AI machines |
|
The color of the machine doesn’t really affect whether doctors or nurses accept AI. What matters more is if they trust it, understand it, and feel it fits into their work. |
This links to technology acceptance models, which focus on factors like trust, usefulness, and ease of use,not appearance.
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
What role does social influence play in AI acceptability in healthcare according to the article?
|
Affects healthcare professionals’ decisions to use AI |
|
If doctors see that their coworkers or hospital leaders are open to using AI, they’re more likely to follow. People often trust what others around them are doing. |
This connects to the social influence part of technology acceptance models, which explains how support from others can make people more willing to try new tools like AI. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
What is a perceived threat regarding AI usage in healthcare settings?
|
Concerns about replacing healthcare professionals |
|
Many healthcare workers worry that AI might take over parts of their jobs. Even if AI is just a tool, the fear of being replaced is real for some people. |
This links to the concept of technological displacement anxiety, which refers to concerns about job security when new tech, like AI, becomes more common in workplaces. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
According to the article, what is essential for increasing AI acceptability among medical professionals?
|
Designing human-centred AI systems |
|
AI works best when it’s designed to help doctors with their real tasks, making their work easier instead of more complicated. That makes them trust and use it more.
|
This is linked to human-centered design, where technology is created with the user’s needs and comfort as a priority. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
What does the 'system usage' category of AI acceptability factors include according to the article?
|
Factors like value proposition and integration with workflows |
|
The usage category talks about how useful AI is and how well it fits into doctors’ everyday work routines. It’s not just about what users like, but how AI helps them do their job better. |
This connects to technology acceptance models, which say that usefulness and ease of integration are key for people to accept new tech like AI. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
How does ethicality impact AI acceptability among healthcare professionals?
|
Affects views on AI based on compatibility with professional values |
|
Healthcare workers accept AI more if it fits with their sense of what’s right and ethical in patient care. If AI goes against their values, they might reject it. |
This connects to ethical frameworks in healthcare, emphasizing that technology must align with professionals’ morals to be accepted.
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
What methodological approach did the article emphasize for future AI acceptability studies?
|
Considering user experience and system integration deeply |
|
The article stresses that to make AI acceptable, research should look closely at how users feel about it and how well AI fits into their daily work.
|
This is based on human-centered research approaches that value user feedback and practical integration for better adoption of technology.
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
What is the primary objective of using human embryonic stem cells in treating Parkinson’s disease?
|
To replace lost dopamine neurons. |
|
Parkinson’s disease happens because dopamine neurons die. Using stem cells aims to grow new dopamine neurons to help the brain work better.
|
This is related to cell replacement therapy, where damaged cells are replaced to restore normal function. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
Which animal was used to test the STEM-PD product for safety and efficacy?
|
Rats |
|
The study used rats because they can safely receive human stem cell products without rejecting them. This helped show that the treatment worked and was safe for Parkinson’s disease models. |
This is related to preclinical testing, where animal models simulate human disease to check if treatments are effective and safe before human trials. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
What was the duration of the preclinical safety study in rats mentioned in the article?
|
9 months |
|
The study lasted 9 months to carefully observe any long-term effects, making sure the treatment is safe before testing in humans. |
This relates to long-term safety testing in preclinical studies, essential to detect delayed side effects or risks.
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
What is the name of the clinical trial phase mentioned for STEM-PD?
|
Phase I |
|
The article mentions the first-in-human clinical trial for STEM-PD, which corresponds to Phase 1, focusing mainly on safety and dosage.
|
Phase 1 trials test safety and determine the right dose before moving on to larger studies. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
How is the STEM-PD product manufactured?
|
Under GMP-compliant conditions |
|
The product is made following strict Good Manufacturing Practice (GMP) rules to ensure it’s safe, consistent, and high-quality for human use.
|
GMP compliance is essential in cell therapy production to meet regulatory standards and protect patients. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
According to the article, what confirmed the safety of the STEM-PD product in rats?
|
There were no adverse effects or tumor formation. |
|
The study found that the treated rats did not have any bad side effects or tumors, which shows the product is safe for further testing. |
Preclinical safety studies look for harmful effects like tumors or immune reactions to ensure the treatment won’t harm humans. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
What key finding was noted in the efficacy study of STEM-PD in rats?
|
Cells showed migration to unintended areas. |
|
The transplanted stem cell-derived cells helped the rats regain movement, showing that the treatment effectively fixed motor problems caused by Parkinson’s disease. |
This reflects successful cell engraftment and functional recovery, key goals in regenerative therapies. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
What specific markers were used to assess the purity of the STEM-PD batch?
|
|
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
What role do growth factors like FGF8b and SHH play in the manufacturing process of STEM-PD?
|
|
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
What was a key outcome measured in the preclinical trials for efficacy in rats?
|
|
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|